证券日报网讯药易购（300937）11月19日在互动平台回答投资者提问时表示，随着冬季呼吸道疾病进入 高发期，公司密切关注医药市场动态，积极发挥医药流通企业的供应链优势，基于公司的药品稳定供应 与保障体系建设并结合市场需求的波动情况，动态调整药品各类库存，致力于保障终端药品的稳定供 应。 ...

Core Points - The Trump administration has confirmed it does not plan to impose tariffs on foreign generic drugs, which account for approximately 90% of the medications used by Americans daily [1][2] - This decision marks a significant reduction in the scope of the Department of Commerce's investigation under the "Section 232" national security framework regarding pharmaceutical products [2] - There are internal divisions within the government regarding the imposition of tariffs on generic drugs, with some officials warning that such tariffs could lead to increased consumer costs and potential drug shortages [3][4] Group 1 - The decision to exclude generic drugs from tariff lists is a reversal of previous commitments made by Trump to bring essential drug production back to the U.S. [2] - The administration is still pursuing the goal of "manufacturing return," considering federal funding or loans for domestic manufacturers of critical generic drugs [1][2] - The potential use of funds from foreign governments, such as Japan, as part of tariff agreements is under consideration, although infrastructure funding has not yet been established [1] Group 2 - Some officials argue that high tariffs on generic drugs may not make domestic production profitable due to the low production costs in countries like India, which supplies nearly half of U.S. generic drugs [3] - Conversely, protectionist officials believe that reliance on foreign suppliers poses a national security risk and that tariffs could incentivize domestic production [3] - The government is adopting a detailed approach to reshape the generic drug manufacturing landscape to avoid supply chain disruptions experienced during the COVID-19 pandemic [3]

Core Points - The company, Realcan Pharmaceutical Group Co., Ltd., was established in December 2009 and is registered in Yantai, Shandong Province with a registered capital of RMB 1,504.71 million [2][3][7] - The company aims to enhance health services through innovation and compliance, focusing on a digital, integrated, and intelligent pharmaceutical supply chain [8][9] - The company has undergone several rounds of public and private share issuance, with the latest being a non-public offering in 2016 [3][10] Company Structure - The company operates as a joint-stock limited company, with its legal representative being the chairman of the board [4] - The company has a total of 150,471.0471 million shares issued, all of which are ordinary shares [11][12] - The company is governed by its articles of association, which outline the rights and responsibilities of shareholders, directors, and senior management [4][16] Business Operations - The company's business scope includes the sale of various medical and pharmaceutical products, including medical devices, health foods, and agricultural products [9] - The company is committed to fulfilling its social responsibilities as a key player in the national pharmaceutical supply chain [8] Shareholder Rights and Responsibilities - Shareholders have the right to receive dividends, participate in shareholder meetings, and access company documents [16][17] - Shareholders are required to report any changes in their shareholding that exceed 3% [22][23] - The company has provisions to protect shareholder interests and ensure compliance with legal obligations [19][20]